Abstracts

Atypical Clinical Presentations Occur in One Third of 293 Patients With a Primary HIV-1 Infection

Background: Proportion and disease-spectrum of atypical clinical presentations in primary HIV-Infection (PHI) has not systematically been studied. Unusual presentation of PHI may lead to delayed diagnosis with impact on transmission. Methodology: Between January 2002 and June 2012 we prospectively enrolled 293 individuals with a well-documented PHI in the Zurich Primary HIV Infection Study, which is…

Association between Number of Acute Retroviral Symptoms and Extended High Viremia by HIV-1 Subtype

Background: Prompt identification of persons with acute HIV infection, particularly those likely to have high viral loads after acute HIV, presents important transmission prevention opportunities. In a large study of HIV-1 seroconverters across 9 sites in Africa, we sought to determine whether the number of signs and symptoms of acute retroviral syndrome (ARS) predicted extended…

Antiviral Therapy and Smoking associated with Coronary Vessel Thickening in HIV-infected Youth

Background: Individuals infected with HIV early in life may be at higher risk for premature vasculopathy and cardiovascular disease. Whether this increased cardiovascular disease risk is associated with chronic HIV-infection or with long-term antiretroviral therapy has yet to be elucidated. The purpose of this study therefore was to assess subclinical coronary vessel wall thickening and…

Soluble CD14 and D-dimer Are Associated With Smoking and Heavy Alcohol Use in HIV-Infected Adults

Background: HIV-infected adults are at increased risk for cardiovascular disease (CVD) compared with uninfected adults. In the general population and among HIV-infected adults, biomarkers of monocyte activation (soluble CD14 [sCD14]) and altered coagulation (D-dimer) have been independently associated with increased risk for myocardial infarction, coronary heart disease, and all-cause mortality. We examined whether cigarette smoking…

The J-curve in HIV: Better Cardiovascular-Disease-Free Survival With Moderate Alcohol Intake

Background: In HIV-negative populations light to moderate alcohol consumption is associated with a lower cardiovascular morbidity and mortality than alcohol abstention. Whether the same holds true for HIV-infected individuals has not been evaluated in detail. Methodology: All adult individuals enrolled in the Swiss HIV Cohort Study who started antiretroviral treatment and had follow-up (fup) time…

SHIV Infection Risk After Rectal Application of a Highly Osmolar Personal Lubricant

Background: Personal lubricant use is common for anal sex. Some water-based products with high osmolality and low pH can damage rectal tissues. Additionally, the preservative polyquaternium 15 (PQ15) can enhance HIV replication in vitro. This has raised concerns that lubricants with such properties may increase STD/ HIV infection risk, although in-vivo evidence is scarce. In…

Efficacy of Vaginal Gel Containing Tenofovir and Emtricitabine Against Rectal SHIV Transmission

Background: Vaginal gels containing tenofovir (TFV) and Emtricitabine (FTC) dose vaginal tissues with high concentrations of drugs and fully protect macaques from vaginal SHIV infection. These vaginal gels also result in drug distribution to the rectum, raising the possibility of bi-compartmental protection. Here, we used pigtail macaques to study the kinetics of rectal drug exposures…

GSK1265744 Long-Acting Protects Macaques against Repeated High-Dose Intravaginal Challenges

Background: GSK1265744 (GSK744) long-acting (LA) is a strand-transfer inhibitor of HIV/SIV integrase (InSTI) formulated as a 200 mg/mL injectable nanoparticle suspension. GSK744 LA is an effective pre-exposure prophylaxis (PrEP) agent against repeated low-dose intrarectal SHIV exposures in male rhesus macaques. This study was performed to evaluate the effectiveness of GSK744 LA as PrEP against high-dose…

Does Tenofovir Gel Alter HIV Disease Progression in CAPRISA 004 Trial Seroconvertors?

Background: While topical and oral antiretroviral pre-exposure prophylaxis (PrEP) prevent HIV acquisition, it is not known if they also alter HIV disease progression in individuals acquiring HIV. This study assesses whether tenofovir (TFV) gel impacted disease progression among women who acquired HIV during the CAPRISA 004 microbicide trial. Methodology: CAPRISA 004 trial seroconvertors were followed…